Foot Care Products - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the foot care products market size was valued at USD 11.23 billion in 2025 and is estimated to grow from USD 12.01 billion in 2026 to reach USD 16.83 billion by 2031, at a CAGR of 6.98% during the forecast period (2026-2031).

This report is Segmented by Product Type (Insoles & Orthotics, Treatments, and Others), Product Form (Cream, Lotion, Gel, Spray, and Others), Application (Medical/Therapeutic, and Others), Distribution Channel (Pharmacies, Supermarkets, and Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Foot Care Products Market Trends and Insights

Rising Diabetic and Aging-Foot Burden

The foot care products market benefits from a growing long-term patient base, with 589 million adults aged 20 to 79 living with diabetes in 2025, representing 1 in 9 adults globally. Of these, 43% or 252 million remained undiagnosed, and 81% resided in low- and middle-income countries, indicating a delayed entry into preventive care pathways. Diabetes-related health expenditure reached USD 1.015 trillion in 2024, a 338% increase over 17 years, highlighting the significant impact of chronic foot-risk conditions on healthcare spending and self-care purchasing. Globally, 6.3% of adults with diabetes experience diabetic foot ulcers, with North America showing a higher prevalence of 13.0%. This drives consistent demand for products like plantar-pressure insoles, medicated creams, antifungal treatments, and protective skin regimens, emphasizing preventive care. Additionally, the aging population sustains demand, with studies supporting the use of arch-support and pressure-redistribution insoles for managing common foot pain.

OTC Shift Toward Preventive Foot Health

The market is witnessing a shift from reactive purchases to planned preventive use, particularly in developed regions where consumers increasingly invest in therapeutic foot products before symptoms worsen. This trend is evident in premium insoles, foot repair creams, and antifungal treatments, which are now positioned closer to daily wellness items. This shift creates a middle tier between low-cost commodities and prescription products, enabling clinically positioned brands to expand their price range while maintaining accessibility. Independent endorsements, such as the American Podiatric Medical Association Seal of Acceptance for ARRIS Composites' AURORRA carbon fiber insoles, are becoming more valuable. Regulatory frameworks also favor established players with robust product testing and compliance systems.

Low Reimbursement for Routine Foot Care

In the U.S., the foot care products market faces structural challenges due to reimbursement policies. Medicare Part B excludes most routine foot care services unless a qualifying systemic condition is properly documented. Consequently, a significant portion of preventive spending becomes out-of-pocket, even for products addressing critical risks like diabetic skin breakdown or fungal recurrence. A 2025 audit revealed that 49% of sampled claims for routine foot care tied to systemic conditions did not meet Medicare requirements. This drives a large segment of the market toward over-the-counter and retail channels, where consumers often prioritize price over long-term value. Expanding coverage for preventive diabetic footwear or related services could significantly impact market growth beyond current forecasts.

Other drivers and restraints analyzed in the detailed report include:

1. Premium Foot Repair and Antifungal Regimens
2. Pharmacy-Led and E-Commerce Discovery
3. PFAS and Material-Compliance Pressure

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Treatment & Condition-Specific Remedies held 42.80% of the foot care products market share, driven by recurring conditions like athlete's foot, fungal nails, and plantar fasciitis. These products benefit from strong shelf visibility, symptom-led merchandising, and ease of selection without formal diagnosis. Foot Skincare & Cosmetic Care has expanded its audience by attracting wellness-focused consumers who integrate foot masks, balms, and exfoliants into regular self-care routines.

Insoles & Orthotics is projected to grow at a CAGR of 8.10% through 2031, supported by the shift from clinic-based customization to digitally accessible retail options. Advanced insole designs, such as lattice-based structures, enhance plantar pressure redistribution, offering brands a strong value proposition for comfort, prevention, and performance. Foot Hygiene & Odor Control remains stable, with probiotic deodorant formats signaling innovation through formulation science.

Cream led the market with a 34.40% share in 2025, owing to its versatility in addressing cosmetic hydration and medicinal treatments. Lotion remains popular for daily moisturization, while gel formats cater to cooling and recovery needs. Patch/Pad/Tape products maintain strong credibility in Europe due to their association with visible protection and symptom relief.

Spray is forecast to grow at a CAGR of 7.20% through 2031, driven by convenience, quick-drying features, and improved suitability for interdigital application. Enhanced propellant systems and carrier technology have enabled sprays to expand into clinically relevant uses. Device and tool formats, such as electronic foot files, create new growth opportunities by linking hardware with consumable products.

Geography Analysis

In 2025, North America accounted for 40.12% of the foot care products market, with the U.S. as the leading center for OTC therapeutic foot care. This dominance is driven by a high disease burden, as 13.0% of adults with diabetes in the region experience diabetic foot ulcers compared to the global average of 6.3%. The region benefits from a strong pharmacy network, high product awareness, and consumer willingness to invest in advanced formulations and insoles. Canada mirrors U.S. purchasing trends in pharmacist-led and self-care categories, while Mexico contributes to volume growth through expanding retail and pharmacy infrastructure.

Europe ranked as the second-largest regional market, with Germany, the U.K., France, Italy, and Spain as key demand centers. Germany stands out due to reimbursement structures and a pharmacy culture that supports a stronger therapeutic mix. Beiersdorf's Health Care division, including Hansaplast, reported growth. Europe is also adapting to material compliance changes, favoring brands transitioning to PFAS-free inputs without compromising performance or pricing.

Asia-Pacific is the fastest-growing region in the foot care products market, with a projected CAGR of 9.35% from 2026 to 2031. China and India lead due to large diabetic populations and growing preventive foot care adoption. By late 2024, China's population aged 60 and above reached nearly 297 million, driving demand for products focused on pressure relief, skin care, and circulation support. Japan follows a mature model, promoting foot care as part of routine health management. The Middle East and Africa benefit from high obesity and diabetes rates in GCC countries, while South America sees growth in antifungal and hygiene products as retail networks expand.

1. Aetrex, Inc.
2. AHAVA Dead Sea Laboratories Ltd.
3. Algeos Limited
4. Bauerfeind
5. Bayer
6. Beiersdorf
7. CURREX
8. Eduard Gerlach GmbH
9. Implus Footcare, LLC
10. Kenvue Inc.
11. KvG Group Inc.
12. O' Keeffe's Company
13. PediFix, Inc.
14. Perrigo Company
15. PowerStep
16. Scholl's Wellness Company Limited
17. SIDAS
18. Spenco
19. Superfeet Worldwide, LLC
20. Tynor Orthotics Private Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support